<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777361</url>
  </required_header>
  <id_info>
    <org_study_id>D3690C00017</org_study_id>
    <secondary_id>EudraCT No.: 2007-005903-16</secondary_id>
    <nct_id>NCT00777361</nct_id>
  </id_info>
  <brief_title>Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy Volunteers</brief_title>
  <acronym>MB</acronym>
  <official_title>An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers With Different CYP2D6 Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed in order to learn more about a new drug (possible as treatment
      for people with Alzheimer's Disease and other conditions with cognitive dysfunction (memory
      and attention problems)) and how it is handled by the body by giving the drug to healthy
      volunteers with different genotypes.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery (% dose) of radioactivity retrieved in urine and faeces Total radioactivity in blood and plasma, AUC, Cmax , tmax, t1/2 and blood/plasma ratio.</measure>
    <time_frame>Urine and faeces collection for at least 168 hours (up to 2 weeks)9 (blood) and 17 (plasma) samples during 48 and 72 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine concentration (AUC, Cmax, tmax, t1/2, F, CL, CLR, fe, Ae, and Vss)</measure>
    <time_frame>19 and 18 blood samples during 72 and 96 hours after iv (Visit 2) and po dosing (Visit 3) respectively. Urine collection for 72 hours and 168 hours (up to 2 weeks).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>identity of major metabolites in plasma and excreta</measure>
    <time_frame>4 blood samples during 8 hours.Urine and faeces collection for at least 168 hours (up to 2 weeks).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events, vital signs (supine blood pressure and pulse rate), ECG, hematology, clinical chemistry and urinalysis.</measure>
    <time_frame>From enrollment to follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AZD3480 iv</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single iv infusion AZD3480</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral [14C] AZD3480</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose [14C]AZD3480</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>Iv single dose, 4-hour infusion of 25 mg</description>
    <arm_group_label>AZD3480 iv</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3480</intervention_name>
    <description>Oral solution single dose of 50 mg</description>
    <arm_group_label>Oral [14C] AZD3480</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically healthy volunteers

          -  Participation in a previous study for genotyping for identification to be extensive,
             intermediate or poor metaboliser (CYP2D6 enzyme)

        Exclusion Criteria:

          -  History of clinically significant diseases or illness.

          -  Ues of any prescribed or non-prescribed medications from 2 weeks prior to first
             treatment day except for paracetamol and OTC adrenergic nasal spray.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Paulsson, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Södertälje, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Mant, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit @ Guy´s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Macclesfield</city>
        <state>Cheshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Björn Paulsson, MD, PhD, Medical Science Director Clinical Neuroscience TA</name_title>
    <organization>AstraZeneca R&amp;D Södertälje</organization>
  </responsible_party>
  <keyword>Mass balance</keyword>
  <keyword>AZD3480, Pharmacokinetics, Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

